Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5006517 | 0.80 | GRM2 (0.36) | CYP1A2CYP2D6PARP1AURKACYP2A6 | |
| SCHEMBL5840948 | 0.78 | GRM2 (0.44) | — | |
| SCHEMBL2157946 | 0.78 | GRM2 (0.35) | ALDH1A1PARP1NPC1RAB9ACYP11B2 | |
| SCHEMBL18894161 | 0.78 | ALDH1A1 (0.34) | TLR8ALKBH5FTOALDH1A1CYP1A2 | |
| SCHEMBL18894190 | 0.78 | ALDH1A1 (0.34) | TLR8ALKBH5FTOALDH1A1CYP1A2 | |
| SCHEMBL18894152 | 0.78 | DAO (0.36) | TLR8ALKBH5FTOALDH1A1CYP1A2 | |
| SCHEMBL1826324 | 0.78 | AURKA (0.35) | TLR8ALKBH5FTOALDH1A1CYP1A2 | |
| SCHEMBL9569254 | 0.76 | JAK2 (0.32) | TLR8CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18894151 | 0.76 | ALDH1A1 (0.33) | TLR8ALKBH5FTOALDH1A1CYP1A2 | |
| SCHEMBL558759 | 0.76 | TLR8 (0.41) | TLR8ALDH1A1CYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144675-A1 | Regulation of sGC Function by Corrin Derivatives | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | claimed |
| US-4578469-A | COUMARIN DYES | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-03-25 | — | — | US | claimed |
| WO-2010146351-A1 | INDOLYLMETHYL-MORPHOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-12-23 | — | — | WO | disclosed |
| US-20100144675-A1 | Regulation of sGC Function by Corrin Derivatives | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-10 | — | — | US | disclosed |
| WO-2008154323-A1 | REGULATION OF sGC FUNCTION BY CORRIN DERIVATIVES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-0745600-B1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5886014-A | TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0745600-A1 | Benzimidazole derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1996-12-04 | — | — | EP | disclosed |
| US-5565469-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1996-10-15 | — | — | US | disclosed |
| CN-1113235-A | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them | THOMAE GMBH DR K (DE) | 1995-12-13 | — | — | CN | disclosed |
| EP-0682021-A1 | Benzimidazoles, medicines containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1995-11-15 | — | — | EP | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | TLR8 4139/4885ALKBH5 184/4885FTO 533/4885 |
| US-20100144675-A1 | Regulation of sGC Function by Corrin Derivatives | GUCY1B1, GUCY1A2, GUCY1A1 | TLR8 3992/4885ALKBH5 2575/4885FTO 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.